Based on this result, fluoxetine was successfully used to treat a DEE patient harboring a de novo missense KCNC1 GOF variant (V425M) resulting in sustained improvement in seizure control, as well as balance, gross motor skills, and oculomotor coordination (Ambrosino et al., 2023). This evidence concerns the gene KCNC1 and developmental and epileptic encephalopathy.